Goldman Sachs on Biotech investments: Curing patients is bad for Business

Herbs that heal would be the worst Case Szenario for Patent based Biotech research

Open list
0 submissions already

Sorry for summing the much more differenciated comment on CNBC like this up, but this time finally a patent pharma investment banker had the balls to speak it out: Healing a disease is bad for cash flow. Whilst many educated citizens suspected that all along, it was nice to hear it from the horses mouth. If you are in need for a long, managable chronic disease, then pharmaceutical products are the way to got.

And before all start with the usual blame game of reckless profiteering: The realty is, few humans invest into something that will cost them most profits and a business that makes it self obsolete. So if we need affordable effective treatments against mostb diseases, it does not make sense to wait for this industry. We have to develop the solutions ourselve. Crowdfunding organized by patient groups its one promising way to go. In the case of the Opioid epidemic we, the People have to develop a natural answer if we want to break free from Addiction. Only short sighted business men would fund such rearch to health our loved ones that became addicted. Are you with us to organize the firt Study on curbing opiat additction by unpatented natural products? We for sure do. In Nature we Trust – Naturetrust.org

And here the promised quote form CNBC:
„The potential to deliver ‚one shot cures‘ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,“ analyst Salveen Richter wrote in the note to clients Tuesday. „While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.“

And later:
Richter cited Gilead Sciences‘ treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company’s U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since.
(end Quote)

Well anyone still wonders why investors lobby against natural alternatives? They are even worse that drugs that heal for business. They heal patients without patents, kill profit margins. And without them the Business can continue as usual. Who would ever expect these Investors to donate money to fake health freedom groups that do false claims on alternative treatments…Well in the case of EU Law there seem to have popped up incredible documents on the Bans if natural therapies:

http://naturetrust.org/2017/10/13/alert-your-politician-about-eu-action-23-now/and destroy pharmaceutical sales.

In order to  get the Study on Kratom going we really would apprecite your input on your experiences. It will healp us to narrow down our focus on the core elemements of the nessessary study.

 

Leave your vote

0 points
Upvote Downvote

Total votes: 0

Upvotes: 0

Upvotes percentage: 0.000000%

Downvotes: 0

Downvotes percentage: 0.000000%

Add your submission

Upload image Embed content

This field is required

Drop files here

oder

Abbrechen

Maximale Dateigröße für Uploads: 2 MB.

Processing...

This field is required

e.g.: https://www.youtube.com/watch?v=WwoKkq685Hk

Processing...

This post was created with our nice and easy submission form. Create your post!

Schreibe einen Kommentar

Deine E-Mail-Adresse wird nicht veröffentlicht. Erforderliche Felder sind mit * markiert.